Skip to main content

Table 1 Univariate analysis. Baseline characteristics/demographics

From: Reduction in new-onset diabetes mellitus after renal transplant with erythropoietin-stimulating agents: a retrospective cohort study

Baseline NODAT No NODAT p value ESA No ESA p value
N = 52 N = 399 N = 132 N = 319
ESA exposure (%) 4 (3) 128 (97)   <0.0001
NODAT Yes (%)   4 (8) 48 (92)
Age at transplant (years) 58.2 ± 11.6 50.7 ± 13.4 0.0001 51.8 ± 13.8 51.4 ± 13.2 0.51
Male (%) 33 (63) 248 (62) 0.89 68 (51) 213 (67) 0.002
Donor source deceased (%) 33 (63) 187 (47) 0.005 78/ (60) 142 (45) 0.005
Body mass index (BMI) 26.9 ± 6.5 26.2 ± 5 0.43 25.8 ± 4.9 26.5 ± 5.3 0.21
Hepatitis C+ yes (%) 0 (0) 4 (1) 0.76 1 (0.7) 3(0.9) 0.63
Acute rejection (AR) yes (%) 2 (4) 26 (6) 0.35 11 (8) 17(5) 0.22
Cause end-stage renal disease:       
 Hypertension 11 33 0.003 11 33 0.51
 Glomerulonephritis 25 196 0.88 70 151 0.27
 Polycystic kidney disease 6 55 0.65 16 45 0.57
 Interstitial nephritis 2 46 0.06 14 34 0.98
 Obstructive uropathy 1 6 0.57 1 6 0.34
 Other 7 63 0.66 20 50 0.88
Blood glucose at start of ESA (N = 13/N = 129) 7.3 ± 2 6.2 ± 1.4 0.04
Blood glucose at the end of ESA (N = 13/N = 129) 5.3 ± 1.5 5.7 ± 1.2 0.08
Tacrolimus IR yes (%) 40 (77) 311 (78) 0.86 104 (79) 247 (77) 0.75
Cyclosporine yes (%) 9 (17) 55 (14) 0.49 11 (8) 53 (16) 0.02
Tacrolimus ER (Advagraf) yes (%) 8 (15) 74 (18.5) 0.67 20 (15) 61 (19) 0.31
Prednisone yes (%) 50 (96) 345 (86) 0.02 121 (92) 274 (86) 0.09
Creatinine (SCr) at initial hospital discharge (umol/L) 162.8 ± 110.2 180.4 ± 147.7 0.32 225.1 ± 188.3 157.5 ± 113 0.0002
 SCr at 3 months (umol/L) 114.3 ± 35.2 127.2 ± 43.6 0.05 136.4 ± 56.5 121.1 ± 34.4 0.005
 SCr at 6 months (umol/L) 119.3 ± 36.7 128.9 ± 49.8 0.10 142.9 ± 70.3 121.1 ± 32.6 0.001
Hemoglobin (Hb) at discharge 98 ± 17.8 98.7 ± 14.9 0.76 93.8 ± 14.8 100.8 ± 15 <.0001
 Hb at 3 months 120.8 ± 16.8 123 ± 17.2 0.41 117.7 ± 16.2 125 ± 16.9 <.0001
 Hb at 6 months 131.6 ± 14.4 128.5 ± 18.2 0.25 123.4 ± 17.3 131.3 ± 17.5 <.0001
Random blood glucose (RBG) at discharge 7.1 ± 2.1 5.8 ± 1.7 <.0001 6 ± 1.8 6 ± 1.8 0.93
 RBG at 3 months 7.7 ± 2.3 5.9 ± 1.3 <.0001 6.2 ± 1.6 6.1 ± 1.7 0.65
 RBG at 6 months 6.9 ± 1.6 5.6 ± 0.9 <.0001 5.5 ± 1 5.8 ± 1.2 0.01
  1. ESAs erythropoietin-stimulating agents, NODAT new-onset diabetes after renal transplant, RBG random blood glucose, BMI body mass index, Hb hemoglobin, SCr serum creatinine